Abstract 1549P
Background
In July 2021, France initiated a significant overhaul of the Early Access (EA) process, replacing the former Authorization for Use (ATU) system. This reform aimed to simplify procedures and expedite access to innovative drugs. This study examined the characteristics of oncology (including onco-hematology) drug approvals through the AE process and assessed the methodological quality of clinical trials supporting these requests.
Methods
All oncology applications submitted to the National Health Authority (HAS) since the EA reform (from July 1, 2021) until December 31, 2023 were identified, reviewing approval decisions, timelines, and reasons for acceptance or rejection. The therapeutic class (ATC) of drugs, cancer site and stage were identified, and the data characterizing clinical trials supporting the requests from reviews provided by HAS and clinicaltrial.gov.
Results
Out of 171 EA approvals (including renewal), 88 (51%) were granted for oncologic indications, with evaluation time by HAS of 71 days on average. Excluding renewals, 48 drugs for 53 indications in oncology received EA approval, predominantly monoclonal antibodies or antibody drug conjugates (49%) and CAR-T cell therapies (17%). Most approved indications were in solid oncology (35, 66%), mainly in digestive (23%), urological (23%), or breast cancers (20%), in metastatic indications in the first-line (31%) or second-line (23%). Onco-hematology authorizations accounted for 18 indications (34%), mostly in the third line and beyond (56%). Oncology drugs approved through the EA pathway were primarily backed by phase III trials (70%), including direct comparison (72%) and/or randomization (70%) whereas refused EA drugs were frequently supported by indirect comparison or non-comparative trials (50%). Overall survival (OS) was included as primary or secondary endpoints in 55% of approved EAs, with mature data available in 36% of trials.
Conclusions
The French EA reform has expedited approval across various indications, facilitating access to innovative drugs like monoclonal antibodies or antibody-drug conjugates, notably in solid oncology for metastatic indications. Ensuring high-quality studies is crucial for EA success, with mature data frequently provided.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10